{"disease":{"id":"transthyretin-related-attr-familial-amyloid-polyneuropathy","name":"transthyretin related attr familial amyloid polyneuropathy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03237494","title":"TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects","phase":"","overall_status":"COMPLETED","enrollment_count":5028,"lead_sponsor_name":"CENTOGENE GmbH Rostock","has_results":false},{"nct_id":"NCT04601051","title":"Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Intellia Therapeutics","has_results":false},{"nct_id":"NCT04418024","title":"Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy","phase":"PHASE3","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Eidos Therapeutics, a BridgeBio company","has_results":false},{"nct_id":"NCT02713880","title":"Biomarker for Transthyretin-Related Familial Amyloidotic Polyneuropathy (BioTRAP)","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"CENTOGENE GmbH Rostock","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}